Evidence map›Paper›PMID 39003253›Full record

ArticleCell death & disease2024

IL-4/IL-4R axis signaling drives resistance to immunotherapy by inducing the upregulation of Fcγ receptor IIB in M2 macrophages.

Jiayu Zhang, Yu Dong, Shan Yu, Keshu Hu, Lingyun Zhang, Min Xiong, Mengling Liu, Xun Sun, Suyao Li, Yitao Yuan and 7 more

Abstract read
In one paragraph

Article in Cell death & disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Role of histone modifications in gastric cancer (Review).International journal of oncology · 2026
    Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Jiayu Zhang *Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.
Yu Dong *Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.
Shan Yu *Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.
Keshu Hu *Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.ORCID 0000-0003-4576-3688
Lingyun Zhang *Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.
Min XiongDepartment of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Center, Shanghai, China.
Mengling LiuDepartment of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.
Xun SunDepartment of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.
Suyao LiDepartment of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.
Yitao YuanDepartment of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.
Chi ZhangDepartment of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.
Mengxuan ZhuDepartment of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.
Yichou WeiDepartment of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.
Yanjing ZhuDepartment of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.
Yiyi YuDepartment of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China. yu.yiyi@zs-hospital.sh.cn.
Pengfei ZhangDepartment of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China. zhang.pengfei@zs-hospital.sh.cn.ORCID 0000-0002-0977-0605
Tianshu LiuDepartment of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China. liutianshu1969@126.com.ORCID 0000-0002-2318-2869

Funding

National Natural Science Foundation of China (National Science Foundation of China) 82802370
6 · The paper itself

Abstract

In recent years, immunotherapy, particularly PD-1 antibodies, have significantly enhanced the outcome of gastric cancer patients. Despite these advances, some patients do not respond well to treatment, highlighting the need to understand resistance mechanisms and develop predictive markers of treatment effectiveness. This study retrospectively analyzed data from 106 patients with stage IV gastric cancer who were treated with first-line immunotherapy in combination with chemotherapy. By comparing plasma cytokine levels between patients resistant and sensitive to PD-1 antibody therapy, the researchers identified elevated IL-4 expression in the resistant patients. Mechanical investigations revealed that IL-4 induces metabolic changes in macrophages that activate the PI3K/AKT/mTOR pathway. This alteration promotes ATP production, enhances glycolysis, increases lactic acid production, and upregulates FcγRIIB expression in macrophages. Ultimately, these changes lead to CD8+ T cell dysfunction and resistance to PD-1 antibody therapy in gastric cancer. These findings highlight the role of IL-4-induced macrophage polarization and metabolic reprogramming in immune resistance and verify IL-4 as potential targets for improving treatment outcomes in gastric cancer patients.

Indexed as

ImmunotherapyInterleukin-4MacrophagesReceptors, IgGSignal TransductionStomach NeoplasmsUp-RegulationAgedAnimalsDrug Resistance, NeoplasmFemaleHumansMaleMiddle AgedReceptors, Interleukin-4IL4 protein, humanInterleukin-4Receptors, IgGReceptors, Interleukin-4

Identifiers

PMID39003253
PMCPMC11246528

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.